Clinical trials: First Pregnancy
Fetal Sex Determination
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies
Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART).
- Trial name
- PREVIEW (NCT01021085)
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Sequenom, Inc.
Metastatic Urothelial Carcinoma
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.
- Trial name
- NCT04863885
- Testing
- Ipilimumab, Nivolumab, Sacituzumab govitecan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
- Conditions
- Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- ONTAK (NCT00880360)
- Testing
- Ontak
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.
Platinum-resistant Ovarian Cancer
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants…
- Trial name
- NCT07226427
- Testing
- MEN2501
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Stemline Therapeutics, Inc.
Ovarian Neoplasms
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO).
- Trial name
- NCT07694427
- Testing
- Mocertatug rezetecan, Bevacizumab
- Where
- 12 sites in Argentina, Australia and 3 more
- Volunteers
- 720 people
- Sponsor
- GlaxoSmithKline
Steroid-Sensitive Nephrotic Syndrome
Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome
All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. One group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks.
- Trial name
- NCT04713410
- Testing
- Prednisolone
- Where
- Pakistan
- Volunteers
- 68 people
- Sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University
Ovarian Cancer
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
This is a single-arm, open-label, multicenter exploratory clinical study designed to evaluate the efficacy and safety of fluzoparib combined with famitinib malate as maintenance therapy in patients with newly diagnosed advanced…
- Trial name
- NCT07382713
- Testing
- Fluzoparib
- Volunteers
- 43 people
- Sponsor
- Jinhua Zhou
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Childbirth
McRoberts Manoeuvre Or Pushing Study (McMOPS)
We propose to conduct a randomised-controlled study to investigate whether adopting McRoberts' position, after 45 minutes of active pushing with no signs of progress, can increase the probability of vaginal delivery, preventing…
- Trial name
- NCT00116246
- Testing
- McRobert's manoeuvre
- Where
- Australia
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Ovarian Cancer
D9319C00001- 1L OC Mono Global RCT
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high…
- Trial name
- MONO-OLA1 (NCT04884360)
- Testing
- Olaparib
- Where
- 89 sites in Chile, China and 8 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV…
- Trial name
- NCT00718523
- Testing
- AMG 479
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 170 people
- Sponsor
- Translational Research in Oncology
Large for Gestational Age (LGA), Pregnancy
Repeat Late GDM Testing and Cesarean Delivery Rates
The goal of this randomized trial is determine if re-testing for gestational diabetes in the third trimester after an ultrasound measurement of estimated fetal weight (EFW) or abdominal circumference greater than 90%ile decreases…
- Trial name
- NCT07708129
- Testing
- Glucose tolerance test and continuous glucose monitor
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shauna F. Williams, MD
Obstetric Labor Complications, Preeclampsia
Platelet Count Trends in Pre-eclamptic Parturients
Thrombocytopenia (platelet count < 100,000/mL) occurs in approximately 15% of women with preeclampsia. Neuraxial analgesia is contraindicated in parturients with a coagulopathy; therefore, the platelet count(PC) is routinely…
- Conditions
- Obstetric Labor Complications, Preeclampsia, Thrombocytopenia
- Trial name
- NCT00787241
- Where
- United States
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Infertility, Female, IVF
RCT to Assess the Impact of Microbiome Status in Infertile IVF Patients at Their First IVF/ICSI Cycle
Although the endometrium has been traditionally considered free of bacteria, recent studies have documented the presence of an endometrial microbiome.
- Trial name
- NCT04686357
- Testing
- EMMA/ALICE
- Volunteers
- 1,018 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Metastatic Renal Cell Carcinoma
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma
Multicentric and prospective epidemiological study (NON INTERVETIONAL) to identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in metstatic renal cell carcinoma.
- Trial name
- SOGANG (NCT03519542)
- Testing
- Sunitinib
- Where
- 12 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where…
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic
- Trial name
- NCT05074472
- Testing
- ZB131
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- ZielBio, Inc.
Birth, First, COVID-19
Online Childbirth Preparation Education in Covid-19 Pandemic
Today, pregnancy and childbirth are important life events that involve many difficulties and changes that must be overcome for both men and women.
- Conditions
- Birth, First, COVID-19, Fear of Childbirth
- Trial name
- NCT05115071
- Testing
- Childbirth preparation education
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pamukkale University
Pregnant Women, First Pregnancy
Biomechanical and Viscoelastic Properties of Thoracolumbar Fascia in Pregnant Women
Pregnancy causes the development of biomechanical adaptations in the musculoskeletal system, especially in the lumbopelvic region.
- Trial name
- NCT05335330
- Testing
- Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia
- Where
- Turkey (Türkiye)
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.